Long Overall Survival After Dendritic Cell Vaccination in Metastatic Uveal Melanoma Patients

Bol, Kalijn F.; Mensink, Hanneke W.; Aarntzen, Erik H.J.G.; Schreibelt, Gerty; Keunen, J. E. E.; Coulie, Pierre G.; Klein, Annelies de; Punt, Cornelis J.A.; Paridaens, Dion; Figdor, Carl G.; Vries, I. Jolanda M. de

doi:10.1016/j.ajo.2014.07.014

Cited by 61 publications

(40 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1) involved autologous DCs exposed to autologous tumor-derived RNA, 196 tumor-cell lysates, [197][198][199][200][201][202][203] autologous tumor stem cell lysates, 204 self-renewing and proliferating autologous tumor cells, 205 allogeneic cancer cell line lysates, [206][207][208] TAAs or TAA-derived peptides [209][210][211][212][213][214][215][216][217][218] or a combination thereof. 219 Most clinical studies based on the latter approach preferred melanoma-associated differentiation antigens including premelanosome protein (PMEL; also known as gp100), antigens belonging to the melanoma antigen gene (MAGE) family, tyrosinase (TYR) and Melan-A (MLANA; also known as MART1) (Fig.…”

Section: Completed Clinical Trialsmentioning

confidence: 99%

“…230 Regarding the distribution across different cancer types ( Fig. 1), patients harboring melanoma were most commonly enrolled in these trials, 186,196,198,205,213,221,223,227,[231][232][233][234] followed by patients with prostate cancer, 206,208,212,215 glioma or glioblastoma (GBM), 185,197,202,219 hepatocellular carcinoma, 204,211,220 non-small cell lung carcinoma (NSCLC), 207,214,230 renal cell carcinoma (RCC), 201,203 esophageal carcinoma, 216,226 and pancreatic ductal adenocarcinoma, 209,217 among others. Of note, only two trials included a wide range of advanced solid tumors refractory to previous treatments.…”

Section: Completed Clinical Trialsmentioning

confidence: 99%

See 1 more Smart Citation

Trial watch: Dendritic cell-based anticancer immunotherapy

et al. 2017

View full text Add to dashboard Cite

Dendritic cell (DC)-based vaccines against cancer have been extensively developed over the past two decades. Typically DC-based cancer immunotherapy entails loading patient-derived DCs with an appropriate source of tumor-associated antigens (TAAs) and efficient DC stimulation through a so-called "maturation cocktail" (typically a combination of pro-inflammatory cytokines and Toll-like receptor agonists), followed by DC reintroduction into patients. DC vaccines have been documented to (re)activate tumor-specific T cells in both preclinical and clinical settings. There is considerable clinical interest in combining DC-based anticancer vaccines with T cell-targeting immunotherapies. This reflects the established capacity of DC-based vaccines to generate a pool of TAA-specific effector T cells and facilitate their infiltration into the tumor bed. In this Trial Watch, we survey the latest trends in the preclinical and clinical development of DC-based anticancer therapeutics. We also highlight how the emergence of immune checkpoint blockers and adoptive T-cell transfer-based approaches has modified the clinical niche for DC-based vaccines within the wide cancer immunotherapy landscape.

show abstract

Section: Completed Clinical Trialsmentioning

confidence: 99%

Section: Completed Clinical Trialsmentioning

confidence: 99%

Trial watch: Dendritic cell-based anticancer immunotherapy

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Ten patients showed stable disease at the first evaluation point, 3 months after start of vaccination, but 7 patients subsequently progressed before the first maintenance cycle of vaccine was started at 6 months. Seven (50%) patients survived more than 2 years after start of DC vaccination for metastatic UM [68] . The efficacy of this therapeutic DC vaccine remains to be investigated in a large prospective study with a more uniform antigenloading method to DC.…”

Section: Vaccinementioning

confidence: 99%

Immunological aspect of the liver and metastatic uveal melanoma

Terai¹,

Mastrangleo²,

Sato³

2017

JCMT

View full text Add to dashboard Cite

Uveal (eye) melanoma is the most common primary eye malignancy in adults. Despite optimal treatments for primary uveal melanoma, up to 50% of patients subsequently develop systemic metastasis, often in the liver. Once hepatic metastasis develops, the survival of patients is generally short and currently available treatments fail to show meaningful improvement of survival. Recent development of immune checkpoint blockades revolutionized immunotherapy for metastatic cutaneous (skin) melanoma. Unfortunately, metastatic uveal melanoma is unresponsive to this approach, thus there is an unmet need to improve the treatment of metastatic uveal melanoma. One unique characteristic of uveal melanoma is that the majority of metastases first develop in the liver. The liver is highly specialized in development of immune tolerance to food-derived antigens and consequently serves a unique function in the immune system. Understanding the mechanisms by which the liver orchestrates immune-related responses is important to the development of an effective immunotherapy for hepatic metastases such as metastatic uveal melanoma. In this review article, the authors overview the immunological aspects of the liver and discuss approaches to improve immunotherapy for metastatic uveal melanoma. Key words:Uveal melanoma, metastasis, liver, liver microenvironment, immunotherapy ABSTRACTArticle history:

show abstract

“…Dendritic cell vaccines have been used to treat several different types of cancer, including melanoma and prostate cancer (31). DeVries observed that melanoma patients who had T-cell infiltrates within their tumor prior to treatment with the dendritic cell vaccine had better survival outcomes.…”

Section: An Ounce Of Preventionmentioning

confidence: 99%

Translating Science into Survival: Report on the Inaugural International Cancer Immunotherapy Conference

Hubbard-Lucey

Tontonoz

2016

Cancer Immunology Research

View full text Add to dashboard Cite

The inaugural International Cancer Immunotherapy Conference, cohosted by the Cancer Research Institute (CRI), the American Association for Cancer Research (AACR), the Association for Cancer Immunotherapy (CIMT), and the European Academy of Tumor Immunology (EATI), was held in New York City on September 16–19, 2015. The conference brought together nearly 1,400 scientists, clinicians, regulators, patient advocates, and other stakeholders to discuss the latest scientific developments in cancer immunology and immunotherapy, as well as the regulatory hurdles facing new drug development. This conference report summarizes the main themes that emerged during the 4-day meeting. Cancer Immunol Res; 4(1); 3–11. ©2016 AACR.

show abstract

Long Overall Survival After Dendritic Cell Vaccination in Metastatic Uveal Melanoma Patients

Cited by 61 publications

References 57 publications

Trial watch: Dendritic cell-based anticancer immunotherapy

Trial watch: Dendritic cell-based anticancer immunotherapy

Immunological aspect of the liver and metastatic uveal melanoma

Translating Science into Survival: Report on the Inaugural International Cancer Immunotherapy Conference

Contact Info

Product

Resources

About